(Q24194821)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

meta-analysis

0 references

title

Bisphosphonate therapy for osteogenesis imperfecta (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

main subject

osteogenesis imperfecta

0 references

author

Robert D. Steiner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Kerry Dwan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Carrie A Phillipi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Donald Basel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

23 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

CD005088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

Intravenous neridronate in adults with osteogenesis imperfecta

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Impact of alendronate on quality of life in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Two doses of pamidronate in infants with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Early bisphosphonate treatment in infants with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Osteogenesis imperfecta: translation of mutation to phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Osteogenesis imperfecta: perspectives and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Type V osteogenesis imperfecta: a new form of brittle bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Genetic heterogeneity in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

PPIB mutations cause severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Bisphosphonate therapy for osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

Lethal neonatal chondrodysplasias in the West of Scotland 1970-1983 with a description of a thanatophoric, dysplasialike, autosomal recessive disorder, Glasgow variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

Do bisphosphonates make children's bones better or brittle?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case-control study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

Osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

GH in combination with bisphosphonate treatment in osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB3

7 January 2021

10.1002/14651858.CD005088.PUB3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25054949%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference